UPDATE: BMO Downgrades Bristol-Myers Squibb

BMO downgraded Bristol-Myers Squibb BMY from Outperform to a Market Perform rating. Alex Arfaei said, "We were wrong to extrapolate the strong efficacy seen with Bristol's Nivo+Yervoy combo in melanoma to lung (NSCLC) and kidney (RCC) cancer." Arfaei later went on to say, "Although BMS still plans to move the combo to phase-3 according to the abstract the doses have not been decided. The future of this combo is uncertain, in our view." Recognizing the number of other IOs in Bristol's pipeline it can combine with Nivo, Arfei believes the given experience with Yervoy+Nivo, the firm is more cautious about other combinations. Bristol-Myers Squibb shares were down 2.41 to $49.71 in pre-market hours Thursday morning. Shares have continued lower, trading at $48.71 at last check.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorDowngradesAnalyst RatingsAlex ArfaeiBMO
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!